Abalone Bio

Abalone Bio addresses challenging undrugged targets that underlie diseases affecting millions, with an initial focus on developing cell-specific antibody drugs to treat obesity and metabolic disease without the gastrointestinal side effects that lead 25% of GLP-1 drug patients to discontinue use after one year. Abalone Bio utilizes high throughput experimental measurement, uniquely leveraging AI/ML by engineering cells to measure antibodies for pharmacological activity rather than just structure or binding. This approach allows for the assessment of 100 million antibodies simultaneously, offering over 100 times the throughput of other methods. The large, proprietary activity datasets enable the use of machine learning to discover rare hits and generate optimized hits for challenging targets, beginning with G-protein coupled receptors (GPCRs). Abalone Bio has demonstrated success by developing antibody agonists for 2 out of the 8 G-protein coupled receptors ever drugged by the biotech industry. The company has secured three partnerships, generating $3 million in revenue and $125 million in downstream value. Its scientific efforts have been externally validated with $7 million in non-dilutive grant funding for platform and program development.